GovBidAlerts
OpenSpecial NoticeFederal

HT9426-27-NOI-049825

Department of Defense · Defense Health Agency (dha)

Due Closes in 42 daysRef. HT9426-27-NOI-049825

At a glance

What

The Defense Health Agency Contracting Activity (DHACA) on behalf of the WRAIR, CMPN, ISB, intends to negotiate on a sole source basis in accordance with RFO 6.103 with vendor Mitochon Pharmaceuticals, Inc. 970 Cross Lane, Blue Bell, PA…

Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (NAICS 541715)

Who can bid
Any business — no set-aside listed
Where
Blue Bell, PA
Key dates
  • Posted: Nov 18, 2026
  • Deadline: Thu, Dec 31, 2026 · 1:00 PM EST (closes in 42 days)
How to respond

Herbert Keen · herbert.e.keen.civ@health.mil · 3016193439

Submit per the instructions on SAM.gov ↗

Documents
None attached here — check SAM.gov

Description

The Defense Health Agency Contracting Activity (DHACA) on behalf of the WRAIR, CMPN, ISB, intends to negotiate on a sole source basis in accordance with RFO 6.103 with vendor Mitochon Pharmaceuticals, Inc. 970 Cross Lane, Blue Bell, PA 19422-1574. The contractor shall supply two (2) Batches of the proprietary prodrug MP201 to ISB for testing Acute Stress Reactions (ASRs). This includes providing quality control documentation and dosage background information. Additionally, the contractor shall provide informational support to the ISB research team by assisting with preparing reports and manuscripts related to MP201. Each batch of synthesized MP201 shall consist of a freshly made lot of prodrug to determine target dosage in the range of approximately 8 - 80 mg/kg body weight. These doses shall be developed in quantities to support oral administration in mice.
Read more ↓
THIS NOI IS NOT A REQUEST FOR COMPETITIVE PROPOSALS, and no solicitation document exists for this requirement. Meaningful submissions received in response to this notice will be considered solely for the purpose of determining whether a competitive procurement is in the best interest of the Government.. Responsible, interested parties may identify their interest by submitting capability statements (using PDF, MS Word, or Excel attachments), in writing, by 2:00 p.m. Eastern Time, 31 December 2026 to Herbert Keen at herbert.e.keen.civ@health.mil and Mr. Lance Nowell at lance.l.nowell.civ@health.mil. Supporting evidence must be furnished in sufficient detail to demonstrate the firms ability to provide the stated capability. Information and materials submitted in response to this request WILL NOT be returned. DO NOT SUBMIT CLASSIFIED MATERIAL. Responses will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon responses to this notice is solely within the discretion of the Government. If no responses are received, the DHACA will proceed with the sole source contract issued to Mitochon Pharmaceuticals, Inc.

Other notices in this solicitation

All notice detailsShow ↓
Solicitation number
HT9426-27-NOI-049825
Notice type
Special Notice
Product/service code (PSC)
AN14
Department
Department of Defense
Sub-agency
Defense Health Agency (dha)
Contracting office
DEFENSE HEALTH AGENCY
Office location
FORT DETRICK, MD, 21702
Place of performance
Mitochon Pharmaceuticals, Inc. 970 Cross Lane, Blue Bell, PA 19422-1574., Blue Bell, PA, 19422
Archive date
Jan 18, 2027
Archive type
autocustom
Organization type
OFFICE
Full agency path
DEPT OF DEFENSE.DEFENSE HEALTH AGENCY (DHA).DEFENSE HEALTH AGENCY
SAM.gov notice ID
f36eb9975e5b4f928396d9d01a0415e5